RE: Mpal on stockbox10 Nov 2025 11:54
The MedPal.clinic platform is initially targeting the rapidly expanding UK weight-loss medication market, specifically GLP-1 agonist treatments, which represents a significant revenue opportunity. Recent research indicates that approximately 2.5 million UK adults either currently use or have strong interest in using GLP-1 drugs for weight loss, with private prescription costs averaging £150-£200 per month. This represents a target addressable market exceeding £500 million in monthly revenue within the UK alone.
Revolutionary Healthcare Delivery Model
MedPal.clinic is powered by the Company's integrated, AI-driven healthcare ecosystem operating around the clock from its recently opened distribution centre at Ecotech Business Park, Swaffham. The key advantages of the platform include:
• Zero-cost consultations: The Company's proprietary AI triage system assesses patient needs in seconds, fast-tracking routine medication requests whilst escalating complex cases to qualified IPs and GPs. Advanced AI triage, combined with robotic dispensing automation, has enabled MedPal to eliminate consultation fees entirely, providing free access to IPs and GPs across the UK - a significant differentiator in the market.
• Multimodal access: maximum communication flexibility allowing patients to engage via text, WhatsApp, or other preferred channels.
• Same-day and next-day delivery: Prescriptions dispensed using state-of-the-art robotic technology (Omnicell VBM and BD Rowa VMAX systems) at the Company's automated 24/7 distribution centre, with rapid nationwide delivery.
By combining artificial intelligence, robotic automation, and human clinical expertise, MedPal.clinic eliminates the traditional bottlenecks in patient care: long wait times, geographic and access constraints, and high costs.